ABBOTT INDIA LTD
Abbott and 1mg Bring Continuous Glucose Monitoring Solutions Closer to Indian homes
MUMBAI, India, 27 July, 2020 — In a move to expand access and empower Indian patients to take charge of their health, Abbott and leading online pharmacy and healthcare platform, 1mg today announced their collaboration to make Abbott's continuous glucose monitoring products available online, including its professional flash glucose monitoring system, FreeStyle® Libre Pro. Patients in India can upload a healthcare practitioner’s prescription and purchase the product online on 1mg. An on-site phlebotomy* service will be provided at the patient’s home with a phlebotomist helping the patient administer the sensor and take readings of the data after 14 days, enabling them to start using the device.
Abbott's FreeStyle Libre Pro consists of a small, round sensor — slightly larger than a 10-rupee coin. A phlebotomist applies the discreet, water-resistant1 and disposable sensor on the back of the upper arm of a patient. The sensor is held in place with a self-adhesive pad and remains on the back of the upper arm for up to 14 days, requiring no patient interaction with the sensor.
"Innovations like the FreeStyle Libre Pro system have transformed the way people manage their glucose levels," said Kalyan Sattaru, general manager of Abbott’s diabetes care business in India. "Making this life-changing technology available online enables more patients to remotely access the care they need, which is especially critical and timely given the current pandemic environment. Our world-leading continuous glucose monitoring will help many more people in India take charge of their condition, and ultimately improve their health."
Commenting on the partnership Prashant Tandon, Co-Founder and CEO of 1mg said, "1mg provides a comprehensive suite of high-quality services for diabetes care, ranging from medicines to doctor consultations, delivered to patients in the comfort and safety of their homes. We are pleased to bring Abbott’s continuous glucose monitoring solutions closer to Indian homes by ensuring easy online access and expert phlebotomy services for FreeStyle Libre Pro application. This is in continuation to our commitment to bring greater access to technology enabled quality care to healthcare consumers."
India’s population living with diabetes today is 77 million, and that number is expected to cross 100 million by 20302. Poor diabetes control, a factor that has been observed in the Indian population with diabetes, puts them at increased risk of health complications including nerve problems, heart diseases, retinopathy and foot ulcers3.
Dr. Shashank Joshi, a leading Endocrinologist and Diabetologist and President, Association of Physicians of India said, “Continuous glucose monitoring helps doctors understand glucose level patterns and equip patients to tailor their lifestyles to achieve their health goals. Making these devices available through an online service that integrates with the convenience of experiencing application will help patients manage their glucose levels better.”
Continuous glucose monitoring devices provides a visual display of a patient's glucose levels over time and how they vary. With this information, patients and their doctors can personalize a treatment plan to help improve patient glucose levels have a greater time in range, i.e., they remain within the recommended limits for longer durations. Abbott's FreeStyle Libre Pro provides this information through continuous glucose monitoring in a visual, easy-to-read graphical format. FreeStyle Libre Pro was launched in India in 2015. Abbott's world-leading continuous glucose monitoring portfolio has benefitted more than 2 million people living with diabetes worldwide.
About FreeStyle Libre Pro - http://www.freestyleindia.com/
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries. In India, Abbott was established in 1910, and is one of the country's oldest and most admired healthcare companies. With over 12,000 employees in the country, Abbott in India is helping to meet the healthcare needs of consumers, patients and doctors throughout urban and rural India.
Connect with us at www.abbott.com and www.abbott.in, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottIndia, and on Twitter @AbbottNews and @AbbottGlobal.
Nandini Goswami, + 91 8291296377
Krishna Vilasini, + 91 8433926550
1 Sensor is water-resistant in up to 1 metre (3 feet) of water and should not be immersed longer than 30 minutes.
2 https://www.idf.org/our-network/regions-members/south-east-asia/members/94-india.html and Harris MI; National Health and Nutrition Examination Survey (NHANES III). Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(6):979-82.
3 Harris MI; National Health and Nutrition Examination Survey (NHANES III). Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(6):979-82.
*Phlebotomy is the process of taking blood from a vein, usually in the upper arm.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.